TIPIRACIL
WNT Pathway
Parabilis Medicines, Inc.Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the WNT Pathway cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Parabilis Medicines, Inc. | Phase 1/2 | CCC |
Irinotecan Parabilis Medicines, Inc. | Phase 1/2 | CCC |
FLUOROURACILUM Parabilis Medicines, Inc. | Phase 1/2 | CCC |
Trifluridine Parabilis Medicines, Inc. | Phase 1/2 | CCC |
Calcium folinate pentahydrate Parabilis Medicines, Inc. | Phase 1/2 | CCC |
(+)-VINCRISTINE Parabilis Medicines, Inc. | Phase 1/2 | CCC |
Nivolumab Parabilis Medicines, Inc. | Phase 1/2 | CCC |
Fog-001 Parabilis Medicines, Inc. | Phase 1/2 | CCC |
Same molecule, other indications
TIPIRACIL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →